Peringatan Keamanan

Animal studies on acute toxicity show that the LD50 of Artemether in mice is a single i.g. administration of 895mg/kg and a single i.m. injection of 296mg/kg dose; in rats, the LD50 is a single i.m. injection of 597mg/kg dose.

Artemether

DB06697

small molecule approved

Deskripsi

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

Struktur Molekul 2D

Berat 298.3746
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Artemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Food increases absorption.

Metabolisme

Rapidly metablized to its active metabolite, dihydroartemisinin.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid grapefruit products.
  • 2. Take with food. Food increases absorption.

Interaksi Obat

919 Data
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Artemether.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Artemether.
Dabrafenib The serum concentration of Artemether can be decreased when it is combined with Dabrafenib.
Pyrimethamine The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether.
Dapsone The risk or severity of QTc prolongation can be increased when Dapsone is combined with Artemether.
Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Artemether.
Quinine The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Artemether.
Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Artemether.
Quinidine The risk or severity of QTc prolongation can be increased when Quinidine is combined with Artemether.
Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Artemether.
Quinacrine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Artemether.
Atovaquone The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether.
Proguanil The risk or severity of QTc prolongation can be increased when Proguanil is combined with Artemether.
Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether.
Sulfadoxine The risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Artemether.
Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether.
Tafenoquine The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Artemether.
Artesunate The risk or severity of QTc prolongation can be increased when Artesunate is combined with Artemether.
Artenimol The risk or severity of QTc prolongation can be increased when Artenimol is combined with Artemether.
Artefenomel The risk or severity of QTc prolongation can be increased when Artefenomel is combined with Artemether.
Chlorproguanil The risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Artemether.
Mizoribine The risk or severity of QTc prolongation can be increased when Mizoribine is combined with Artemether.
Pyronaridine The risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Artemether.
Artemisinin The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Artemether.
Artemotil The risk or severity of QTc prolongation can be increased when Artemotil is combined with Artemether.
Piperaquine The risk or severity of QTc prolongation can be increased when Piperaquine is combined with Artemether.
Tetrandrine The risk or severity of QTc prolongation can be increased when Tetrandrine is combined with Artemether.
Cycloguanil The risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Artemether.
Luliconazole The serum concentration of Artemether can be increased when it is combined with Luliconazole.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Artemether.
Perampanel The metabolism of Perampanel can be increased when combined with Artemether.
Efavirenz The metabolism of Artemether can be increased when combined with Efavirenz.
Warfarin The metabolism of Warfarin can be increased when combined with Artemether.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Artemether.
(R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Artemether.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Artemether.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Artemether.
(S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Artemether.
Etravirine The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.
Thiethylperazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Thiethylperazine.
Promazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Prochlorperazine.
Triflupromazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Triflupromazine.
Fluphenazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Fluphenazine.
Thioridazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Thioridazine.
Moricizine The risk or severity of QTc prolongation can be increased when Artemether is combined with Moricizine.
Trifluoperazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Trifluoperazine.
Perphenazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Perphenazine.
Mesoridazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Mesoridazine.
Acetophenazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Acetophenazine.
Promethazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Promethazine.
Alimemazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Alimemazine.
Methotrimeprazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Methotrimeprazine.
Periciazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Periciazine.
Acepromazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Acepromazine.
Aceprometazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Aceprometazine.
Pipotiazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Pipotiazine.
Thioproperazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Thioproperazine.
BL-1020 The risk or severity of QTc prolongation can be increased when Artemether is combined with BL-1020.
Cyamemazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Cyamemazine.
Methylene blue The risk or severity of QTc prolongation can be increased when Artemether is combined with Methylene blue.
Propiopromazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Propiopromazine.
Perazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Perazine.
Butaperazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Butaperazine.
Chlorproethazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Chlorproethazine.
Thiazinam The risk or severity of QTc prolongation can be increased when Artemether is combined with Thiazinam.
Dixyrazine The risk or severity of QTc prolongation can be increased when Artemether is combined with Dixyrazine.
Perphenazine enanthate The risk or severity of QTc prolongation can be increased when Artemether is combined with Perphenazine enanthate.
Lumacaftor The serum concentration of Artemether can be decreased when it is combined with Lumacaftor.
Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Artemether.
St. John's Wort The serum concentration of dihydroartemisinin, an active metabolite of Artemether, can be decreased when used in combination with St. John's Wort.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Artemether.
Erythromycin The serum concentration of Artemether can be increased when it is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Artemether.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Artemether.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Artemether.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Artemether.
Clozapine The risk or severity of QTc prolongation can be increased when Artemether is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Artemether.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Artemether.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Artemether.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Artemether.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Artemether.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Artemether.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Artemether.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Artemether.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Artemether.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Artemether.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Artemether.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Artemether.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Artemether.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Artemether.
Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Artemether.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Artemether.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Artemether.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Artemether.

Target Protein

Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1

Referensi & Sumber

Synthesis reference: Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. Pubmed(http://www.ncbi.nlm.nih.gov/pubmed/8053018).
Artikel (PubMed)
  • PMID: 19818172
    Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5.
  • PMID: 23409819
    Mutabingwa TK, Adam I: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169.
  • PMID: 8053018
    Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Coartem
    Tablet • - • Oral • US • Approved
  • Coartem
    Tablet • - • Oral • US • Approved
  • Coartem
    Tablet • - • Oral • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul